Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of “Moderate Buy” from Analysts

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $16.8333.

A number of brokerages have recently commented on ALT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 15th. Citizens Jmp decreased their price target on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a report on Friday, November 7th. Citigroup restated a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Monday, October 20th.

Altimmune Stock Performance

Shares of Altimmune stock opened at $4.14 on Tuesday. The firm has a market capitalization of $431.97 million, a P/E ratio of -3.87 and a beta of -0.03. Altimmune has a 12 month low of $2.90 and a 12 month high of $8.25. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08. The business’s fifty day simple moving average is $4.52 and its 200 day simple moving average is $4.39.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.08. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. As a group, analysts anticipate that Altimmune will post -1.35 EPS for the current year.

Insider Buying and Selling at Altimmune

In other news, Director Jerome Benedict Durso bought 12,500 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The stock was bought at an average price of $4.13 per share, for a total transaction of $51,625.00. Following the transaction, the director directly owned 12,500 shares of the company’s stock, valued at $51,625. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Altimmune by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after purchasing an additional 2,241 shares in the last quarter. MetLife Investment Management LLC lifted its stake in Altimmune by 5.4% in the first quarter. MetLife Investment Management LLC now owns 46,870 shares of the company’s stock worth $234,000 after purchasing an additional 2,396 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Altimmune by 10.9% in the second quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock worth $108,000 after purchasing an additional 2,748 shares during the last quarter. Deutsche Bank AG boosted its position in Altimmune by 3.9% during the first quarter. Deutsche Bank AG now owns 79,851 shares of the company’s stock valued at $399,000 after buying an additional 3,026 shares during the period. Finally, Concurrent Investment Advisors LLC grew its stake in shares of Altimmune by 16.4% during the second quarter. Concurrent Investment Advisors LLC now owns 25,258 shares of the company’s stock valued at $98,000 after buying an additional 3,565 shares during the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.